Topics
News
CME/CE
Editorial Advisory Board
Partners
Subscribe
- Case-Based Roundtable
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
- Buy-and-Bill
Article
Stiefel Laboratories acquires ABR Invent and ABR Development
Coral Gables, Fla. - Stiefel Laboratories announces the acquisition of ABR Invent and ABR Development, developers of the dermal filler Atlean, PRNewswire reports.
Coral Gables, Fla.
- Stiefel Laboratories announces the acquisition of ABR Invent and ABR Development, developers of the dermal filler Atlean, PRNewswire reports.
Stiefel will acquire all shares of ABR Invent and ABR Development through a definitive stock purchase agreement. Both Invent and Development are based in France.
Atlean(R) is a bio-resorbable, sculpting and modeling dermal filler with hyaluronic acid and tricalcium phosphate particles. Atlean(R) received a CE-Mark granted in 2006 and is marketed in France and Italy, according to PRNewswire.
Related Videos
Related Content
